Amylyx Pharmaceuticals (AMLX) Projected to Announce Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.3810) per share and revenue of $0.06 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, analysts expect Amylyx Pharmaceuticals to post ($1.48) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Performance

Shares of Amylyx Pharmaceuticals stock opened at $29.20 on Wednesday. The company has a fifty day simple moving average of $30.50 and a 200-day simple moving average of $20.20. Amylyx Pharmaceuticals has a 12-month low of $10.83 and a 12-month high of $41.14.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, Director George M. Milne, Jr. sold 30,000 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director directly owned 782,881 shares of the company’s stock, valued at approximately $21,685,803.70. This represents a 3.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James M. Frates sold 10,810 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the sale, the chief financial officer owned 233,625 shares of the company’s stock, valued at $7,560,105. This trade represents a 4.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 60,374 shares of company stock valued at $1,815,257. Company insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Citigroup boosted their target price on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, October 15th. Mizuho upped their target price on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Finally, Robert W. Baird lifted their price target on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $40.71.

Amylyx Pharmaceuticals Company Profile